|
Endometriosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The present study was conducted to determine the presence or absence of aromatase expression in peritoneal endometriotic implants and in the eutopic endometrium of women with endometriosis.
|
8550748 |
1996 |
|
Endometriosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Aromatase expression in PGE2-stimulated stromal cells of endometriosis is regulated primarily by the classically located promoter II, which, in turn, is regulated by cAMP.
|
9024261 |
1997 |
|
Endometriosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
We conclude that the recently developed potent aromatase inhibitors are candidate drugs in the treatment of endometriosis that is resistant to standard regimens.
|
9548162 |
1998 |
|
Endometriosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Aberrant aromatase expression in stromal cells of endometriosis gives rise to conversion of circulating androstenedione to estrone in this tissue, whereas aromatase expression is absent in the eutopic endometrium.
|
9851796 |
1998 |
|
Endometriosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Expression of aromatase cytochrome P450 in eutopic endometrium and its application as a diagnostic test for endometriosis.
|
10559661 |
1999 |
|
Endometriosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The clinical relevance of aromatase expression in endometriosis was shown recently by the successful treatment of an unusually aggressive case of postmenopausal endometriosis with use of an aromatase inhibitor.
|
10593363 |
1999 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The clinical relevance of these findings was exemplified by the successful treatment of an unusually aggressive case of postmenopausal endometriosis with an aromatase inhibitor.
|
10652502 |
2001 |
|
Endometriosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In contrast, aromatase is expressed aberrantly in endometriosis and is stimulated by prostaglandin E(2) (PGE(2)).( )This results in local production of estrogen, which induces PGE(2) formation and establishes a positive feedback cycle.
|
10915216 |
2000 |
|
Endometriosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Aromatase, however, is expressed inappropriately in endometriosis and stimulated by prostaglandin E2.
|
11045871 |
2001 |
|
Endometriosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The presence of aromatase, a key enzyme in the biosynthesis of estradiol, has been demonstrated in eutopic endometrial samples of women with moderate to severe endometriosis, but not in those of disease-free women.
|
11502834 |
2001 |
|
Endometriosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In contrast, aromatase is expressed aberrantly in endometriosis and is stimulated by PGE2.
|
11850203 |
2001 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The results suggest that the 3 bp I/D polymorphism of the CYP19 gene may be weakly associated with the susceptibility of endometriosis in a Japanese population.
|
11925378 |
2002 |
|
Endometriosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Regulation of aromatase P450 expression in endometriotic and endometrial stromal cells by CCAAT/enhancer binding proteins (C/EBPs): decreased C/EBPbeta in endometriosis is associated with overexpression of aromatase.
|
11994385 |
2002 |
|
Endometriosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In contrast, aromatase is expressed aberrantly in endometriosis and is stimulated by PGE(2).
|
12062819 |
2002 |
|
Endometriosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Recent studies demonstrate that endometriosis per se express high levels of estrogen synthetase (aromatase P450).
|
12161505 |
2002 |
|
Endometriosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Among the novel potential candidate drugs, aromatase inhibitors and raloxifene should be considered for treatment of postmenopausal women with endometriosis.
|
12372439 |
2002 |
|
Endometriosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Aromatase, calhedrin, oestrogen receptor, galactose-1-phosphate uridyl transferase (GALT) and tumour suppressor genes such as p53 are attractive candidate genes for endometriosis.
|
12475548 |
2002 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The CYP19 VNTR, located in intron 4 (TTTA)(10) allele increases the risk for endometriosis development (odds ratio [OR], 4.99; 95% confidence interval [95% CI], 1.351 to 18.436).
|
12620480 |
2003 |
|
Endometriosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas.
|
12620485 |
2003 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The polymorphisms in the ER-alpha gene, the CYP19 gene encoding aromatase, and several other genes are associated with the risk of endometriosis.
|
12650711 |
2002 |
|
Endometriosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Aromatase P450 expression in the human endometrium is thought to be restricted to women with proliferative reproductive tract disorders such as endometriosis, leiomyomas and adenomyosis.
|
14747179 |
2004 |
|
Endometriosis
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
In fact, pilot trials showed that aromatase inhibitors could decrease pelvic pain associated with endometriosis.
|
15083380 |
2004 |
|
Endometriosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, two potential negative regulators of aromatase expression, chicken ovalbumin upstream promoter transcription factor 2 (COUP-TF2) and prostaglandin E2 receptor subtype EP3 (PGE2EP3), were downregulated in endometriosis epithelial cells, which might result in increased local production of estrogen in endometriosis epithelial cells.
|
15299092 |
2004 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Here, we evaluated whether the risk and severity of endometriosis are associated with polymorphisms in estradiol-synthesizing enzyme genes: the Ser312Gly polymorphism in 17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1) and the Arg264Cys polymorphism in cytochrome P450, subfamily XIX (CYP19).
|
15640252 |
2005 |
|
Endometriosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Successful treatment of endometriosis and uterine leiomyomata using aromatase inhibitors by recent pilot trials underscores the clinical significance of these molecular studies.
|
16024248 |
2005 |